Lawless A, Effiom DN, Burbano A, Sharova T, et al. Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response. Ann Surg Oncol 2026 May 23. doi: 10.1245/s10434-026-19814.
PMID: 42177374